In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

AbbVie’s deal with Alpine on Thursday is its second innovative partnership in as many weeks, giving the company an option to a Phase II-ready therapy for lupus, a disease that has seen only one targeted therapy approved in the past 50 years.

For Alpine Immune Sciences Inc. (NASDAQ:ALPN), the $60 million upfront payment will enable it to advance its portfolio of fusion proteins for cancer and B cell-mediated diseases on its own. The biotech’s stock more than doubled Thursday,

Read the full 791 word article

How to gain access

Continue reading with a
two-week free trial.